Vaccinex

Vaccinex Equity

The The Equity of Vaccinex (VCNX) as of Nov 20, 2026 is -7.59 M USD. In the previous year, The Equity was -2.49 M USD — a change of 205.10% (lower).

Equity

-7.59 MUSD

YoY

205.10%

Last updated:

In 2025, Vaccinex's equity was -7.59 M USD, a 205.10% increase from the -2.49 M USD equity in the previous year.

The Vaccinex Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-8.62 M USD
Jan 1, 2019
-26.24 M USD
Jan 1, 2020
-26.58 M USD
Jan 1, 2021
7.41 M USD
Jan 1, 2022
5.19 M USD
Jan 1, 2023
-2.31 M USD
Jan 1, 2024
-2.49 M USD
Jan 1, 2025
-7.59 M USD
The Vaccinex Equity history
YEAREquityYoY
-7.59 MUSD+205.10%
-2.49 MUSD+7.66%
-2.31 MUSD-144.50%
5.19 MUSD-29.94%
7.41 MUSD-127.89%
-26.58 MUSD+1.29%
-26.24 MUSD+204.34%
-8.62 MUSD+386.51%
-1.77 MUSD-46.77%
-3.33 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaccinex Stock analysis

What does Vaccinex do? Vaccinex, Inc. develops targeted biotherapeutics for serious diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The company generates revenue through its SEMA4D antibody platform, focusing on VX15 for non-small cell lung cancer, osteosarcoma, melanoma, and Huntington’s disease. It also utilizes the ActiveMAb antibody discovery platform for developing VX5, which is in preclinical stages for multiple sclerosis and other autoimmune disorders. Vaccinex targets healthcare providers and pharmaceutical companies seeking novel treatments for unmet medical needs. Vaccinex's lead product candidate VX15 is developed using the SEMA4D platform to address non-small cell lung cancer, osteosarcoma, and melanoma. The company's ActiveMAb platform supports the creation of high-affinity human monoclonal antibodies, which are used in VX5 for multiple sclerosis treatment. These platforms enable Vaccinex to offer innovative solutions for diseases with limited therapeutic options. The company's focus on clinical-stage development means it currently does not generate revenue from product sales but relies on partnerships and potential future licensing agreements. Vaccinex's target segments include patients with non-small cell lung cancer, osteosarcoma, melanoma, Huntington’s disease, and multiple sclerosis, as well as pharmaceutical companies interested in acquiring or co-developing its platforms and product candidates. Vaccinex is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Vaccinex's Equity

Vaccinex's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vaccinex's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vaccinex's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vaccinex's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vaccinex’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vaccinex stock

The Equity of Vaccinex is -7.59 M USD in 2025.

The Equity of Vaccinex changed from -2.49 M USD to -7.59 M USD, representing a 205.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Vaccinex since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Vaccinex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vaccinex

All Key Metrics — Vaccinex